In its release on the CARDIO-TTRansform data, the ESC echoed AZ and Ionis’ point that Wainua suppressed circulating serum TTR ...

Mimrylo marks the second FDA new drug approval that Takeda has secured since CEO Julie Kim officially took the reins in June ...

In their high-profile competition in the diabetes and obesity markets, Eli Lilly has proven adept in playing catch up with ...

For decades, drugmakers have been confounded in the clinic by a rare form of hypertrophic cardiomyopathy. | Cytokinetics' ...

RevMed’s leadership, too, highlighted the significance of Rasonque’s approval in a call with investors yesterday.

The FDA approval of Bixlenvo tees up a new HIV treatment option for virologically suppressed adults, including those on ...

Amgen and AstraZeneca’s inflammatory disease drug Tezspire has clinched a phase 3 win in eosinophilic esophagitis (EoE) as ...

Though not without a bump along the way, Roivant-backed Priovant Therapeutics has pushed its dual TYK2/JAK1 inhibitor across ...

By Alicia Cowley, MD, MBA, Medical Director, Phreesia Network Solutions | Endemic media and broad reach each do half the job.

Biogen’s late-stage lupus candidates may not have crossed the FDA finish line yet, but the company has already hit the ground ...

With a potential $2.5 billion deal with Hanmi, Roche is taking a less-trodden path in obesity. | Roche is taking a ...

On Wednesday, the U.S. Court of Appeals for the Fifth Circuit affirmed (PDF) a previous ruling in district court rebuffing ...